Induction of mitochondrial changes in myeloma cells by imexon

Katerina Dvorakova, Caroline N. Waltmire, Claire M. Payne, Margaret E Tome, Margaret M Briehl, Robert T Dorr

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Imexon is a cyanoaziridine derivative that has antitumor activity in multiple myeloma. Previous studies have shown that imexon induces oxidative stress and apoptosis in the RPMI 8226 myeloma cell line. This study reports that imexon has cytotoxic activity in other malignant cell lines including NCI-H929 myeloma cells and NB-4 acute promyelocytic leukemia cells, whereas normal lymphocytes and U266 myeloma cells are substantially less sensitive. Flow cytometric experiments have shown that imexon treatment is associated with the formation of reactive oxygen species (ROS) and the loss of mitochondrial membrane potential (Δψ m) in imexon-sensitive myeloma cell lines and NB-4 cells. In contrast, reduction of Δψ m and increased levels of ROS were not observed in imexon-resistant U266 cells. Treatment of imexon-sensitive RPMI 8226 cells with the antioxidant N-acetyl-L-cysteine (NAC) protects cells against these effects of imexon. Mitochondrial swelling was observed by electron microscopy in RPMI 8226 myeloma cells treated with 180 μM imexon as early as 4 hours. Damage to mitochondrial DNA was detected by a semiquantitative polymerase chain reaction assay in imexontreated RPMI 8226 cells; however, nuclear DNA was not affected. Finally, partial protection of RPMI 8226 cells against the imexon effects was achieved by treatment with theonyltrifluoroacetone, an inhibitor of superoxide production at mitochondrial complex II. These changes are consistent with mitochondrial oxidation and apoptotic signaling as mediators of the growth inhibitory effects of imexon. Interestingly, oxidative damage and decrease of Δψ m induced by imexon highly correlates with sensitivity to imexon in several myeloma cell lines and an acute promyelocytic leukemia cell line.

Original languageEnglish (US)
Pages (from-to)3544-3551
Number of pages8
JournalBlood
Volume97
Issue number11
DOIs
StatePublished - Jun 1 2001

Fingerprint

Cells
Cell Line
Acute Promyelocytic Leukemia
4-imino-1,3-diazabicyclo(3.1.0)hexan-2-one
Reactive Oxygen Species
Mitochondrial Swelling
Oxidative stress
Lymphocytes
Mitochondrial Membrane Potential
Polymerase chain reaction
Acetylcysteine
Multiple Myeloma
Mitochondrial DNA
Superoxides
Electron microscopy
Swelling
Assays
Electron Microscopy
Oxidative Stress
Antioxidants

ASJC Scopus subject areas

  • Hematology

Cite this

Induction of mitochondrial changes in myeloma cells by imexon. / Dvorakova, Katerina; Waltmire, Caroline N.; Payne, Claire M.; Tome, Margaret E; Briehl, Margaret M; Dorr, Robert T.

In: Blood, Vol. 97, No. 11, 01.06.2001, p. 3544-3551.

Research output: Contribution to journalArticle

Dvorakova, Katerina ; Waltmire, Caroline N. ; Payne, Claire M. ; Tome, Margaret E ; Briehl, Margaret M ; Dorr, Robert T. / Induction of mitochondrial changes in myeloma cells by imexon. In: Blood. 2001 ; Vol. 97, No. 11. pp. 3544-3551.
@article{671d101ec6754180be5fd40bce02d753,
title = "Induction of mitochondrial changes in myeloma cells by imexon",
abstract = "Imexon is a cyanoaziridine derivative that has antitumor activity in multiple myeloma. Previous studies have shown that imexon induces oxidative stress and apoptosis in the RPMI 8226 myeloma cell line. This study reports that imexon has cytotoxic activity in other malignant cell lines including NCI-H929 myeloma cells and NB-4 acute promyelocytic leukemia cells, whereas normal lymphocytes and U266 myeloma cells are substantially less sensitive. Flow cytometric experiments have shown that imexon treatment is associated with the formation of reactive oxygen species (ROS) and the loss of mitochondrial membrane potential (Δψ m) in imexon-sensitive myeloma cell lines and NB-4 cells. In contrast, reduction of Δψ m and increased levels of ROS were not observed in imexon-resistant U266 cells. Treatment of imexon-sensitive RPMI 8226 cells with the antioxidant N-acetyl-L-cysteine (NAC) protects cells against these effects of imexon. Mitochondrial swelling was observed by electron microscopy in RPMI 8226 myeloma cells treated with 180 μM imexon as early as 4 hours. Damage to mitochondrial DNA was detected by a semiquantitative polymerase chain reaction assay in imexontreated RPMI 8226 cells; however, nuclear DNA was not affected. Finally, partial protection of RPMI 8226 cells against the imexon effects was achieved by treatment with theonyltrifluoroacetone, an inhibitor of superoxide production at mitochondrial complex II. These changes are consistent with mitochondrial oxidation and apoptotic signaling as mediators of the growth inhibitory effects of imexon. Interestingly, oxidative damage and decrease of Δψ m induced by imexon highly correlates with sensitivity to imexon in several myeloma cell lines and an acute promyelocytic leukemia cell line.",
author = "Katerina Dvorakova and Waltmire, {Caroline N.} and Payne, {Claire M.} and Tome, {Margaret E} and Briehl, {Margaret M} and Dorr, {Robert T}",
year = "2001",
month = "6",
day = "1",
doi = "10.1182/blood.V97.11.3544",
language = "English (US)",
volume = "97",
pages = "3544--3551",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Induction of mitochondrial changes in myeloma cells by imexon

AU - Dvorakova, Katerina

AU - Waltmire, Caroline N.

AU - Payne, Claire M.

AU - Tome, Margaret E

AU - Briehl, Margaret M

AU - Dorr, Robert T

PY - 2001/6/1

Y1 - 2001/6/1

N2 - Imexon is a cyanoaziridine derivative that has antitumor activity in multiple myeloma. Previous studies have shown that imexon induces oxidative stress and apoptosis in the RPMI 8226 myeloma cell line. This study reports that imexon has cytotoxic activity in other malignant cell lines including NCI-H929 myeloma cells and NB-4 acute promyelocytic leukemia cells, whereas normal lymphocytes and U266 myeloma cells are substantially less sensitive. Flow cytometric experiments have shown that imexon treatment is associated with the formation of reactive oxygen species (ROS) and the loss of mitochondrial membrane potential (Δψ m) in imexon-sensitive myeloma cell lines and NB-4 cells. In contrast, reduction of Δψ m and increased levels of ROS were not observed in imexon-resistant U266 cells. Treatment of imexon-sensitive RPMI 8226 cells with the antioxidant N-acetyl-L-cysteine (NAC) protects cells against these effects of imexon. Mitochondrial swelling was observed by electron microscopy in RPMI 8226 myeloma cells treated with 180 μM imexon as early as 4 hours. Damage to mitochondrial DNA was detected by a semiquantitative polymerase chain reaction assay in imexontreated RPMI 8226 cells; however, nuclear DNA was not affected. Finally, partial protection of RPMI 8226 cells against the imexon effects was achieved by treatment with theonyltrifluoroacetone, an inhibitor of superoxide production at mitochondrial complex II. These changes are consistent with mitochondrial oxidation and apoptotic signaling as mediators of the growth inhibitory effects of imexon. Interestingly, oxidative damage and decrease of Δψ m induced by imexon highly correlates with sensitivity to imexon in several myeloma cell lines and an acute promyelocytic leukemia cell line.

AB - Imexon is a cyanoaziridine derivative that has antitumor activity in multiple myeloma. Previous studies have shown that imexon induces oxidative stress and apoptosis in the RPMI 8226 myeloma cell line. This study reports that imexon has cytotoxic activity in other malignant cell lines including NCI-H929 myeloma cells and NB-4 acute promyelocytic leukemia cells, whereas normal lymphocytes and U266 myeloma cells are substantially less sensitive. Flow cytometric experiments have shown that imexon treatment is associated with the formation of reactive oxygen species (ROS) and the loss of mitochondrial membrane potential (Δψ m) in imexon-sensitive myeloma cell lines and NB-4 cells. In contrast, reduction of Δψ m and increased levels of ROS were not observed in imexon-resistant U266 cells. Treatment of imexon-sensitive RPMI 8226 cells with the antioxidant N-acetyl-L-cysteine (NAC) protects cells against these effects of imexon. Mitochondrial swelling was observed by electron microscopy in RPMI 8226 myeloma cells treated with 180 μM imexon as early as 4 hours. Damage to mitochondrial DNA was detected by a semiquantitative polymerase chain reaction assay in imexontreated RPMI 8226 cells; however, nuclear DNA was not affected. Finally, partial protection of RPMI 8226 cells against the imexon effects was achieved by treatment with theonyltrifluoroacetone, an inhibitor of superoxide production at mitochondrial complex II. These changes are consistent with mitochondrial oxidation and apoptotic signaling as mediators of the growth inhibitory effects of imexon. Interestingly, oxidative damage and decrease of Δψ m induced by imexon highly correlates with sensitivity to imexon in several myeloma cell lines and an acute promyelocytic leukemia cell line.

UR - http://www.scopus.com/inward/record.url?scp=0035383778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035383778&partnerID=8YFLogxK

U2 - 10.1182/blood.V97.11.3544

DO - 10.1182/blood.V97.11.3544

M3 - Article

C2 - 11369649

AN - SCOPUS:0035383778

VL - 97

SP - 3544

EP - 3551

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -